RAD
Radiopharm Theranostics Ltd
Director Trades
| Date | Director | Value |
|---|---|---|
| : Riccardo Canevari | $37,500 | |
| I. Turner | $87,000 | |
| I. Turner | $33,800 | |
| R. Canevari | $19,859 |
Company News
Radiopharm Theranostics Granted Ethics Approval for RAD402 Phase 1 Trial to Treat Advanced Prostate Cancer
Radiopharm Theranostics (ASX: RAD) has received Bellberry human research ethics committee approval in Australia for a Phase 1 first in-human clinical trial of RAD402 for the treatment of metastatic or locally-advanced prostate cancer.
Starpharma and Radiopharm Theranostics Partner to Develop Novel Radiotherapy Asset
Starpharma Holdings (ASX: SPL) has entered into a research and option partnership with Radiopharm Theranostics (ASX: RAD) to develop and manufacture a dendrimer drug conjugate incorporating a radiopharmaceutical molecule to target certain cancers. The partnership, which follows six months of preliminary research under Starpharma’s Star Navigator drug development program, will see Radiopharm pay Starpharma a $500,000 for an […]
Radiopharm Theranostics Receives FDA Investigational New Drug Clearance for RV-01 Cancer Therapy
Radiopharm Theranostics (ASX: RAD) has received investigational new drug clearance from the US Food and Drug Administration (FDA) for therapeutic candidate Betabart (RV-01). RV-01 targets the B7H3 immune checkpoint molecule that plays a role in cancer development and progression. The FDA clearance will now allow the company to initiate a first-in-human Phase 1 clinical trial […]
Radiopharm Theranostics earns FDA approval for brain metastasis imaging agent RAD 101
Clinical-stage biopharmaceutical company Radiopharm Theranostics (ASX: RAD) has received clearance from the US Food and Drug Administration (FDA) for an investigational new drug (IND) application relating to F18-Pivalate (RAD 101). RAD 101 is a proprietary imaging agent currently under clinical investigation for the detection and characterisation of brain metastases. Labelled with the radioisotope F18, pivalate […]
Radiopharm Theranostics secures $70m in funding with major stake from Lantheus Holdings
US-based radiopharmaceuticals industry leader Lantheus Holdings has agreed to make a hefty investment into a $70 million equity raising by Australian biotech Radiopharm Theranostics (ASX: RAD). The funds raised through share placement will be used by Radiopharm for manufacturing and clinical trials of its oncology drugs over the next two years. Long-term commitment Lantheus has […]
Australian biotech sector tipped for strong growth
Recent studies have highlighted the significant potential the Australian biotech industry has ahead of it. International research firm KPMG recently forecast Australia could generate over $15 billion in exports to the United States and create 34,000 high-skilled jobs by accelerating US-Australia biotechnology collaboration. Australia’s $1.2b biotech industry currently ranks fifth in the world in terms […]
Radiopharm Theranostics advances cancer treatment with RAD 301 and RAD 302 developments
Radiopharm Theranostics (ASX: RAD) has welcomed the release of new data identifying a promising pathway for its innovative RAD 301 and RAD 302 oncology developments. Multiple new data covering the RAD 301 and RAD 302 programs were featured at the 2024 European Molecular Imaging Meeting (EMIM) in Portugal this week. RAD 302, which is currently […]
Radiopharm Theranostics doses first patient in RAD 301 pancreatic cancer study
Biotechnology company Radiopharm Theranostics (ASX: RAD) has dosed the first patient in a Phase 1 study assessing the safety, dosimetry and imaging characteristics of the RAD 301 isotope in the treatment of advanced pancreatic cancer. The patient was dosed with 68Ga-Trivehexin (RAD 301) to target the αvβ6 integrin in the detection of lesions relating to […]
Radiopharm Theranostics set to revolutionise prostate cancer treatment with Terbium-161
A recent medical publication into prostate cancer has validated the development by clinical-stage biotech Radiopharm Theranostics (ASX: RAD) of its first-in-class Terbium-161 (Tb-161). The publication reported the results of six metastatic castration-resistant prostate cancer patients who were treated with Tb-161 and lutetium chloride (Lu-177). It demonstrated that Tb-161 could deliver markedly higher tumor-absorbed doses compared […]
Radiopharm Theranostics boosts clinical trials pipeline with $1.9m R&D advance
Radiopharm Theranostics (ASX: RAD) continues to build up its bank balance with the receipt of $1.9 million as an advance on its anticipated FY24 research and development (R&D) tax incentive (RDTI). The funds have been provided by Radium Capital and are to be mostly used to support Radiopharm’s clinical trial pipeline. Repayment to Radium Capital […]
